{"analyses":[{"ciLowerLimit":"1.48","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.04","estimateComment":"Reference level = Hormone Therapy + Radiation Therapy","groupDescription":"Gray's test was used to compare cumulative incidence between treatment arms (1-sided significance level of 0.025) and the Fine-Gray model was used to calculate hazard ratios.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Hazard Ratio (HR)","paramValue":"1.74","statisticalMethod":"Gray's test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.4","upperLimit":"29.2","value":"26.3"},{"groupId":"OG001","lowerLimit":"37.9","upperLimit":"44.4","value":"41.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"987"},{"groupId":"OG001","value":"992"}],"units":"Participants"}],"description":"The Phoenix definition of biochemical failure was used - an increase in the prostate-specific antigen (PSA) level of \\>2 ng per milliliter above the nadir. Failure rates were estimated by means of cumulative incidence functions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Neoadjuvant total androgen suppression (TAS) - Flutamide and Zoladex or Lupron - two months before and during radiation therapy.","id":"OG000","title":"Hormone Therapy + Radiation Therapy"},{"description":"Radiation therapy alone","id":"OG001","title":"Radiation Therapy Alone"}],"paramType":"NUMBER","populationDescription":"All eligible patients.","reportingStatus":"POSTED","timeFrame":"From registration to 10 years","title":"Biochemical Failure Rate (10 Years)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}